This increased risk of bleeding in patients after ibrutinib treatment is attributed to on-target BTK inhibition, as patients with X-linked agammaglobulinemia (absence of BTK expression and defects in platelet aggregation) do not develop excessively bleeding deformities [92]. The gene discussed is BTK; the disease is Bruton-type agammaglobulinemia.